Table 1 Baseline patient characteristics
Characteristic (N = 855) | Patients aged > 70 years | Patients aged ≤ 70 years |
|---|---|---|
Total number of patients | 193 | 662 |
Median age, years (range) | 75 (71–88) | 55 (16–70) |
Male/female, n (%) | 112 (58)/81 (42) | 348 (53)/314 (47) |
ECOG performance status, n (%) | ||
0 | 105 (54) | 458 (69) |
1 | 83 (43) | 184 (28) |
2 | 5 (3) | 20 (3) |
Time from diagnosis, months (range) | 35 (3–280) | 40 (3–280) |
LDH level, n/n (%)a | ||
< 1.10 ULN | 108/175 (62) | 336/545 (62) |
≥ 1.10 ULN | 67/175 (38) | 209/545 (38) |
Number of previous therapies, n (%) | ||
1 | 128 (66) | 369 (56) |
2 | 41 (21) | 192 (29) |
≥ 3 | 24 (13) | 101 (15) |
Previous therapy, n (%) | ||
Dacarbazine | 113 (59) | 377 (57) |
Fotemustine | 54 (28) | 268 (41) |
Platinum-based chemotherapy | 42 (22) | 274 (41) |
Temozolomide | 40 (21) | 149 (23) |
Interferon | 22 (11) | 172 (26) |
BRAF inhibitor | 8 (4) | 51 (8) |
Patients with brain metastases, n (%) | 17 (9) | 129 (20) |
Patients with liver metastases, n (%) | 75 (39) | 264 (40) |